Pernix Therapeutics Holdings (NASDAQ:PTX) : The most positive equity analysts on Pernix Therapeutics Holdings (NASDAQ:PTX) expects the shares to touch $10, whereas, the least positive believes that the stock will trade at $3 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $6.5 with an expected fluctuation of $4.95 from the mean.
Pernix Therapeutics Holdings, Inc. has lost 11.93% in the last five trading days and dropped 3.86% in the last 4 weeks. Pernix Therapeutics Holdings, Inc. has dropped 56.92% during the last 3-month period . Year-to-Date the stock performance stands at -84.81%.
Pernix Therapeutics Holdings (NASDAQ:PTX) has an average broker rating of 2.33, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 5, which is also a Strong Sell.
Pernix Therapeutics Holdings (NASDAQ:PTX): The stock opened at $0.47 on Thursday but the bulls could not build on the opening and the stock topped out at $0.47 for the day. The stock traded down to $0.45 during the day, due to lack of any buying support eventually closed down at $0.45 with a loss of -2.88% for the day. The stock had closed at $0.46 on the previous day. The total traded volume was 2,986,720 shares.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).